Opportunity Information: Apply for RFA DK 27 108
The NIH is soliciting applications to continue the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) Consortium through a U01 cooperative agreement mechanism. The central goal is to sustain and expand a collaborative, interdisciplinary research effort that uses a shared cardiovascular-focused repository to deepen understanding of why people with type 1 diabetes (T1D) face such high rates of cardiovascular disease (CVD), and how CVD in T1D may differ in its biology, trajectory, and clinical presentation from CVD in other populations. This opportunity is explicitly research-focused and does not allow clinical trials, meaning the work should center on observational, mechanistic, translational, analytic, and repository-driven studies rather than testing interventions in a trial framework.
The scientific rationale behind the funding is the persistent and outsized burden of cardiovascular complications in T1D. CVD remains the leading cause of death for individuals with T1D and substantially reduces life expectancy. Despite progress in managing traditional risk factors such as hyperglycemia, hypertension, and dyslipidemia, many patients still experience a significant residual cardiovascular risk even under what would be considered optimal control. The NOFO highlights that key disease mechanisms in T1D remain incompletely understood across multiple domains, including atherosclerosis, diabetic cardiomyopathy (both diastolic and systolic dysfunction), endothelial dysfunction, and cardiac autonomic neuropathy. These gaps matter because there are currently no therapies specifically approved to prevent or treat several of these common, severe cardiovascular complications in T1D, particularly cardiomyopathy-related pathways that contribute heavily to morbidity and mortality alongside atherosclerotic disease.
Programmatically, the opportunity is intended to keep the CaRe-T1D consortium operating as a coordinated national resource rather than a collection of disconnected projects. Applicants should expect the cooperative agreement structure to involve substantial NIH programmatic involvement and coordination expectations typical of U01 awards, with an emphasis on team science, harmonized methods, shared governance, and data or biospecimen resource stewardship. The underlying idea is that a continuing repository and consortium model can accelerate discovery by enabling larger, well-characterized datasets, standardized phenotyping, reproducible analyses, and cross-study comparisons that would be difficult for any single lab or center to achieve alone.
This NOFO is supported through the Special Diabetes Program, a congressionally supported initiative that funds research aimed at preventing, treating, and ultimately curing T1D and its complications. In that context, CaRe-T1D is positioned as a specialized consortium resource focused on cardiovascular outcomes and mechanisms, aligning with the program's emphasis on unique, innovative, and collaborative consortia and networked research efforts. While the notice does not list specific required aims in the provided excerpt, the described priorities point toward projects that can leverage and enrich the existing CaRe-T1D infrastructure to clarify pathophysiology, identify novel risk markers or mechanistic pathways, and explain why standard risk-factor modification does not fully eliminate cardiovascular risk in T1D.
Key administrative details are as follows. The funding opportunity title is "Continuation of the Cardiovascular Repository for Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition) - Research (U01, Clinical Trial Not Allowed)." The funding opportunity number is RFA-DK-27-108. The sponsor is the National Institutes of Health (NIH), and the instrument is a cooperative agreement (U01). The activity category is Health, and the CFDA/Assistance Listing numbers include 93.233, 93.837, 93.838, 93.839, 93.840, and 93.847. The application closing date listed is 2027-03-10. The expected number of awards is 8, and the award ceiling is $500,000 (as stated in the source data).
Eligibility is broad across many U.S.-based organization types, including state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education institutions in those categories as specified); for-profit organizations other than small businesses; and small businesses. However, foreign eligibility is restricted: non-U.S. entities are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. At the same time, foreign components as defined by NIH policy are allowed, which typically means a U.S. applicant may include certain foreign elements in the project when well-justified and compliant with NIH Grants Policy Statement definitions, even though the applicant organization and primary components must remain domestic.
Overall, the opportunity is aimed at sustaining a national collaborative platform to tackle a stubborn clinical problem: cardiovascular disease that continues to claim lives in T1D even when conventional risk factors are addressed. The emphasis is on advancing mechanistic understanding and improving the research ecosystem (data, specimens, standardized measures, and interdisciplinary collaboration) necessary to develop future preventive and therapeutic strategies, while staying firmly in the non-clinical-trial research lane required by the NOFO.Apply for RFA DK 27 108
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840, 93.847.
- This funding opportunity was created on 2026-06-04.
- Applicants must submit their applications by 2027-03-10.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 8 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity?
The NIH is soliciting applications to continue the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) Consortium through a U01 cooperative agreement. The funding opportunity title is "Continuation of the Cardiovascular Repository for Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition) - Research (U01, Clinical Trial Not Allowed)."
What is the funding opportunity number (NOFO/RFA number)?
The funding opportunity number is RFA-DK-27-108.
Who is the sponsor of this opportunity?
The sponsor is the National Institutes of Health (NIH).
What type of award mechanism is being used?
This opportunity uses a U01 cooperative agreement mechanism, which typically involves substantial NIH programmatic involvement and coordination expectations.
Are clinical trials allowed under this NOFO?
No. This is a research opportunity where clinical trials are not allowed. The work is expected to focus on observational, mechanistic, translational, analytic, and repository-driven studies rather than testing interventions in a clinical trial framework.
What is the overall goal of continuing the CaRe-T1D Consortium?
The central goal is to sustain and expand a collaborative, interdisciplinary research effort that uses a shared cardiovascular-focused repository to better understand why people with type 1 diabetes (T1D) experience high rates of cardiovascular disease (CVD), and how CVD in T1D may differ from CVD in other populations in terms of biology, trajectory, and clinical presentation.
Why is NIH prioritizing cardiovascular disease research in type 1 diabetes?
The scientific rationale is the persistent and outsized cardiovascular burden in T1D. CVD remains the leading cause of death for individuals with T1D and reduces life expectancy. Even with progress in managing traditional risk factors (such as hyperglycemia, hypertension, and dyslipidemia), many people with T1D still have substantial residual cardiovascular risk under what would be considered optimal control.
What types of cardiovascular complications and mechanisms are highlighted as gaps in knowledge?
The NOFO highlights that key disease mechanisms in T1D remain incompletely understood across multiple domains, including atherosclerosis, diabetic cardiomyopathy (both diastolic and systolic dysfunction), endothelial dysfunction, and cardiac autonomic neuropathy.
What is meant by a "repository" in this consortium context?
Based on the description provided, the repository is a shared cardiovascular-focused resource intended to support research by enabling larger, well-characterized datasets, standardized phenotyping, reproducible analyses, and cross-study comparisons. It is positioned as a coordinated national resource rather than separate, disconnected projects.
What research approach does NIH expect from applicants?
The opportunity emphasizes team science and coordinated consortium operations, including harmonized methods, shared governance, and stewardship of data and/or biospecimen resources. The intent is to support collaborative, interdisciplinary research that leverages and enriches the existing CaRe-T1D infrastructure.
What kinds of studies are a good fit, given that clinical trials are not allowed?
The notice frames the work as observational, mechanistic, translational, analytic, and repository-driven research. The described priorities point toward studies that clarify pathophysiology, identify novel risk markers or mechanistic pathways, and help explain why standard risk-factor modification does not fully eliminate cardiovascular risk in T1D.
How is this opportunity positioned programmatically within NIH?
This NOFO is supported through the Special Diabetes Program, a congressionally supported initiative that funds research aimed at preventing, treating, and ultimately curing type 1 diabetes and its complications. CaRe-T1D is positioned as a specialized consortium resource focused on cardiovascular outcomes and mechanisms.
What is the activity category for this opportunity?
The activity category is Health.
What are the CFDA/Assistance Listing numbers associated with this opportunity?
The CFDA/Assistance Listing numbers include 93.233, 93.837, 93.838, 93.839, 93.840, and 93.847.
When is the application closing date?
The application closing date listed is 2027-03-10.
How many awards does NIH expect to make?
The expected number of awards is 8.
What is the award ceiling?
The award ceiling is $500,000 (as stated in the source data provided).
Who is eligible to apply?
Eligibility is broad across many U.S.-based organization types, including state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education institutions in those categories as specified); for-profit organizations other than small businesses; and small businesses.
Are non-U.S. (foreign) organizations eligible to apply as the main applicant?
No. Non-U.S. entities are not eligible to apply.
Can a U.S. applicant include non-U.S. components in the project?
Non-U.S. components of U.S. organizations are not eligible. However, foreign components (as defined by NIH policy) are allowed, which generally means certain foreign elements may be included when well-justified and consistent with NIH Grants Policy definitions, even though the applicant organization and primary components must remain domestic.
What does the cooperative agreement structure imply for awardees?
The cooperative agreement structure implies substantial NIH programmatic involvement and coordination expectations typical of U01 awards, with an emphasis on coordinated consortium operations, team science, harmonized methods, shared governance, and resource stewardship.
Is this opportunity focused on building a coordinated national resource or on independent projects?
It is intended to keep CaRe-T1D operating as a coordinated national resource rather than a collection of disconnected projects.
What problem is this consortium trying to address in practical terms?
The consortium is aimed at advancing understanding of why cardiovascular disease continues to claim lives in type 1 diabetes even when conventional risk factors are addressed. The emphasis is on improving the research ecosystem (data, specimens, standardized measures, and interdisciplinary collaboration) needed to support future preventive and therapeutic strategies, while staying within the non-clinical-trial scope.
Are there existing therapies specifically approved for several cardiovascular complications in T1D?
The provided description notes that there are currently no therapies specifically approved to prevent or treat several common, severe cardiovascular complications in T1D, particularly cardiomyopathy-related pathways that contribute to morbidity and mortality alongside atherosclerotic disease.
Browse more opportunities from the same category: Health
Next opportunity: GLS Campus Suicide Prevention Grant Program
Previous opportunity: National Professional Development Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 27 108
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 27 108) also looked into and applied for these:
| Funding Opportunity |
|---|
| Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY) (U24- Clinical Trials Not Allowed) Apply for RFA DK 27 126 Funding Number: RFA DK 27 126 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases Apply for CDC RFA CK 26 0107 Funding Number: CDC RFA CK 26 0107 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $30,000,000 |
| Strengthening tuberculosis (TB) prevention, diagnosis, treatment, and surveillance in Asia Apply for CDC RFA JG 26 0125 Funding Number: CDC RFA JG 26 0125 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Enhancing sustainable health information and laboratory systems and networks for quality detection, management, and monitoring to end HIV and TB as public health threats in India Apply for CDC RFA JG 26 0143 Funding Number: CDC RFA JG 26 0143 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Sustaining life-saving HIV services in Ukraine by strengthening resilient health systems under the Ukraine Ministry of Health, Public Health Center Apply for CDC RFA JG 26 0172 Funding Number: CDC RFA JG 26 0172 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) Apply for RFA AI 27 004 Funding Number: RFA AI 27 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Metastasis Research Network (U54 Clinical Trial Not Allowed) Apply for RFA CA 27 012 Funding Number: RFA CA 27 012 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed) Apply for PAR 27 021 Funding Number: PAR 27 021 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities. Apply for CDC RFA CK 26 0221 Funding Number: CDC RFA CK 26 0221 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $1,250,000 |
| Increasing awareness and knowledge of Alpha-gal Syndrome in the United States Apply for CDC RFA CK 26 0193 Funding Number: CDC RFA CK 26 0193 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $1,000,000 |
| National Child Traumatic Stress Initiative - Treatment and Service Adaptation (TSA) Centers Apply for SM 26 003 Funding Number: SM 26 003 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $600,000 |
| National Center for Child Traumatic Stress - Category 1 Apply for SM 26 002 Funding Number: SM 26 002 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $8,000,000 |
| GLS Campus Suicide Prevention Grant Program Apply for SM 26 009 Funding Number: SM 26 009 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $125,000 |
| Project AWARE (Advancing Wellness and Resiliency in Education) Apply for SM 26 005 Funding Number: SM 26 005 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,500,000 |
| National Child Traumatic Stress Initiative - Community Treatment and Service Centers (CTS) Apply for SM 26 004 Funding Number: SM 26 004 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $600,000 |
| Adult Suicide Prevention Apply for SM 26 007 Funding Number: SM 26 007 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $400,000 |
| Providers Clinical Support System - Universities Apply for TI 26 001 Funding Number: TI 26 001 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $300,000 |
| Cooperative Agreements for Certified Community Behavioral Health Clinic (CCBHC) Planning Grants Apply for SM 26 016 Funding Number: SM 26 016 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,000,000 |
| Certified Community Behavioral Health Clinics (CCBHCs) Planning, Development, and Implementation Grant Apply for SM 26 014 Funding Number: SM 26 014 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,000,000 |
| Consumer and Consumer Support Technical Assistance Center Apply for SM 26 017 Funding Number: SM 26 017 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,782,291 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 27 108", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.